2024-19720. Medical Devices; Neurological Devices; Classification of the Digital Therapy Device for Attention Deficit Hyperactivity Disorder  

  • Table 1—Digital Therapy Device for Attention Deficit Hyperactivity Disorder Risks and Mitigation Measures

    Identified risks to health Mitigation measures
    Ineffective treatment leading to worsening or uncontrolled symptoms Clinical performance testing, and Labeling.
    Device software failure leading to delayed access Software verification and validation, and Labeling.
    Treatment results in frustration, emotional reaction, dizziness, nausea, headache, eye-strain, or joint pain Labeling; Clinical performance testing; and Software verification, validation, and hazard analysis.
    Treatment results in seizure Labeling, and Clinical performance testing.
    Treatment results in screen addiction Labeling, and Clinical performance testing.
    Treatment results in decreased sleep quality Labeling, and Clinical performance testing.

Document Information

Effective Date:
9/3/2024
Published:
09/03/2024
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final amendment; final order.
Document Number:
2024-19720
Dates:
This order is effective September 3, 2024. The classification was applicable on June 15, 2020.
Pages:
71155-71156 (2 pages)
Docket Numbers:
Docket No. FDA-2024-N-3992
Topics:
Medical devices
PDF File:
2024-19720.pdf
CFR: (1)
21 CFR 882